Shares of Accuray Inc. (NASDAQ:ARAY) traded down 3.7% on Thursday . The stock traded as low as $4.90 and last traded at $4.90, with a volume of 288,689 shares changing hands. The stock had previously closed at $5.09.

Several analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research report on Monday, April 11th. Morgan Stanley reiterated a “hold” rating on shares of Accuray in a research report on Wednesday, April 27th. Finally, Brean Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Accuray in a research report on Sunday, May 22nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. Accuray presently has an average rating of “Hold” and a consensus price target of $8.58.

The company’s 50-day moving average is $5.25 and its 200-day moving average is $5.55. The company’s market cap is $420.00 million.

Accuray (NASDAQ:ARAY) last announced its earnings results on Tuesday, April 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.07. During the same period last year, the firm posted ($0.04) EPS. The company had revenue of $105.30 million for the quarter, compared to the consensus estimate of $102.79 million. The company’s revenue was up 8.0% compared to the same quarter last year. Equities analysts forecast that Accuray Inc. will post ($0.27) earnings per share for the current year.

Other large investors have made changes to their positions in the company. Lapides Asset Management LLC raised its stake in shares of Accuray by 1.8% in the fourth quarter. Lapides Asset Management LLC now owns 2,149,500 shares of the company’s stock valued at $14,509,000 after buying an additional 38,600 shares during the period. Wells Fargo & Company MN raised its stake in shares of Accuray by 20.9% in the fourth quarter. Wells Fargo & Company MN now owns 1,656,069 shares of the company’s stock valued at $11,178,000 after buying an additional 286,458 shares during the period. Boston Partners raised its stake in shares of Accuray by 10.8% in the fourth quarter. Boston Partners now owns 4,272,040 shares of the company’s stock valued at $28,836,000 after buying an additional 417,568 shares during the period. Neuberger Berman Group LLC raised its stake in shares of Accuray by 16.0% in the fourth quarter. Neuberger Berman Group LLC now owns 2,800,295 shares of the company’s stock valued at $18,902,000 after buying an additional 385,220 shares during the period. Finally, Russell Frank Co raised its stake in shares of Accuray by 24.0% in the fourth quarter. Russell Frank Co now owns 1,028,628 shares of the company’s stock valued at $7,077,000 after buying an additional 198,874 shares during the period.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.